BioCentury | Sep 2, 2020
Deals

How J&J reeled in Momenta in $6.5B deal while barely raising its bid

...of Momenta last month, although J&J barely sweetened its offer from its first proposal while Momenta’s...
...on a day when Momenta’s shares closed at $39.27, with the bid representing a 27% premium.Momenta’s...
...Momenta’s shares had dipped to $34 at that time. While the due diligence process continued, Momenta...
BioCentury | Aug 25, 2020
Regulation

Politics & plasma: a BioCentury podcast

...Johnson and Johnson buying Momenta for $6.5 billion. That deal came about two years after Momenta...
BioCentury | Aug 21, 2020
Finance

CF Foundation’s Longwood incubator fund to push early tech toward CF

...operational capacity, have co-founded companies that include Acceleron Pharma Inc. (NASDAQ:XLRN), Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY), Momenta Pharmaceuticals Inc....
BioCentury | Aug 19, 2020
Deals

Momenta’s shift to innovative pipeline pays off with $6.5B J&J takeout

...Myasthenia gravis POC readout closely preceded pharma’s premium bid By Paul Bonanos, Associate Editor Momenta’s 2018...
...the deal’s primary drivers; J&J will assess what to do with the rest of Momenta’s pipeline.Momenta...
...Momenta’s shares dipped below $10. They had traded in the mid-$20s shortly before the restructuring began.Momenta...
BioCentury | Jan 17, 2020
Company News

Jan. 17 Company Quick Takes: FDA expands label of Novo’s Ozempic; plus Intercept, Durect, Coherus-Innovent, CoImmune-Formula and Momenta

...CAR T approaches (see “Formula’s Italian CAR” ). Momenta buoyed by ITP readout Shares of Momenta Pharmaceuticals Inc....
...by an upgrade from J.P. Morgan, which raised its price target to $30 from $14; Momenta...
...Informal) Ocaliva, obeticholic acid (DSP-1747, 6ecdca, int-747, oca) Novo Nordisk A/S Intercept Pharmaceuticals Inc. Durect Corp. Innovent Biologics Inc. Coherus BioSciences Inc. Momenta Pharmaceuticals Inc. CoImmune...
BioCentury | Jan 4, 2020
Company News

Management tracks: Fountain Medical taps Zhen as CEO; plus DBV, Momenta reveal CFO succession plans

...since August following the departure of principal financial officer David Schilansky. Immunology and biosimilars company Momenta Pharmaceuticals Inc....
BioCentury | Dec 12, 2019
Financial News

Trio of follow-ons lift 2019 tally of deals

...Well Short of 2018's Total" ). At least three other companies--Forty Seven Inc. (NASDAQ:FTSV) and Momenta Pharmaceuticals Inc....
...designation for CDKL5 deficiency disorder, for which top-line Phase III data are due in 3Q20. Momenta...
...via a follow-on. -Staff Writer Elizabeth Eaton contributed to this report. Val Kennedy, Associate Editor Constellation Pharmaceuticals Inc. Momenta Pharmaceuticals Inc. Marinus...
BioCentury | Dec 12, 2019
Financial News

Momenta, Forty Seven, Assembly push 2019 follow-on tally to $21.5B

...$27 billion but approaching the $22.6 billion raised in 2017, according to BioCentury’s BCIQ database. Momenta Pharmaceuticals Inc....
...AG (NYSE:NVS) over Lovenox enoxaparin and generic enoxaparin. The settlement is subject to court approval. Momenta...
...the sale was proposed. Assembly gained $6.10 (34%) Thursday to close at $23.81. Val Kennedy, Associate Editor Momenta Pharmaceuticals Inc. Forty...
BioCentury | Jun 21, 2019
Politics, Policy & Law

Fearmongering about China diminishes American life sciences competitiveness

...an investment in the online patient platform PatientsLikeMe and reportedly scuttled a Chinese investment in Momenta Pharmaceuticals Inc....
...see “CFIUS Drawing Line In Sand On Personal Data” and “CFIUS Influence May Have Prompted Momenta’s...
...not necessarily reflect the views of BioCentury. Companies and Institutions Mentioned iCarbonX Inc. (Shenzhen, China) Momenta Pharmaceuticals Inc....
BioCentury | Jun 5, 2019
Finance

Conflicts over scale, response to foreign threats and espionage against NIH research at Senate hearing

...an online platform for patients to share health information, and prevented a Chinese investment in Momenta Pharmaceuticals Inc....
...“CFIUS Drawing Line In Sand On Personal Data, ” and “CFIUS influence May Have Prompted Momenta's...
...in “some nefarious activity.” Companies and Institutions Mentioned Oregon Health & Science University, Portland, Ore. Momenta Pharmaceuticals Inc....
Items per page:
1 - 10 of 401
BioCentury | Sep 2, 2020
Deals

How J&J reeled in Momenta in $6.5B deal while barely raising its bid

...of Momenta last month, although J&J barely sweetened its offer from its first proposal while Momenta’s...
...on a day when Momenta’s shares closed at $39.27, with the bid representing a 27% premium.Momenta’s...
...Momenta’s shares had dipped to $34 at that time. While the due diligence process continued, Momenta...
BioCentury | Aug 25, 2020
Regulation

Politics & plasma: a BioCentury podcast

...Johnson and Johnson buying Momenta for $6.5 billion. That deal came about two years after Momenta...
BioCentury | Aug 21, 2020
Finance

CF Foundation’s Longwood incubator fund to push early tech toward CF

...operational capacity, have co-founded companies that include Acceleron Pharma Inc. (NASDAQ:XLRN), Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY), Momenta Pharmaceuticals Inc....
BioCentury | Aug 19, 2020
Deals

Momenta’s shift to innovative pipeline pays off with $6.5B J&J takeout

...Myasthenia gravis POC readout closely preceded pharma’s premium bid By Paul Bonanos, Associate Editor Momenta’s 2018...
...the deal’s primary drivers; J&J will assess what to do with the rest of Momenta’s pipeline.Momenta...
...Momenta’s shares dipped below $10. They had traded in the mid-$20s shortly before the restructuring began.Momenta...
BioCentury | Jan 17, 2020
Company News

Jan. 17 Company Quick Takes: FDA expands label of Novo’s Ozempic; plus Intercept, Durect, Coherus-Innovent, CoImmune-Formula and Momenta

...CAR T approaches (see “Formula’s Italian CAR” ). Momenta buoyed by ITP readout Shares of Momenta Pharmaceuticals Inc....
...by an upgrade from J.P. Morgan, which raised its price target to $30 from $14; Momenta...
...Informal) Ocaliva, obeticholic acid (DSP-1747, 6ecdca, int-747, oca) Novo Nordisk A/S Intercept Pharmaceuticals Inc. Durect Corp. Innovent Biologics Inc. Coherus BioSciences Inc. Momenta Pharmaceuticals Inc. CoImmune...
BioCentury | Jan 4, 2020
Company News

Management tracks: Fountain Medical taps Zhen as CEO; plus DBV, Momenta reveal CFO succession plans

...since August following the departure of principal financial officer David Schilansky. Immunology and biosimilars company Momenta Pharmaceuticals Inc....
BioCentury | Dec 12, 2019
Financial News

Trio of follow-ons lift 2019 tally of deals

...Well Short of 2018's Total" ). At least three other companies--Forty Seven Inc. (NASDAQ:FTSV) and Momenta Pharmaceuticals Inc....
...designation for CDKL5 deficiency disorder, for which top-line Phase III data are due in 3Q20. Momenta...
...via a follow-on. -Staff Writer Elizabeth Eaton contributed to this report. Val Kennedy, Associate Editor Constellation Pharmaceuticals Inc. Momenta Pharmaceuticals Inc. Marinus...
BioCentury | Dec 12, 2019
Financial News

Momenta, Forty Seven, Assembly push 2019 follow-on tally to $21.5B

...$27 billion but approaching the $22.6 billion raised in 2017, according to BioCentury’s BCIQ database. Momenta Pharmaceuticals Inc....
...AG (NYSE:NVS) over Lovenox enoxaparin and generic enoxaparin. The settlement is subject to court approval. Momenta...
...the sale was proposed. Assembly gained $6.10 (34%) Thursday to close at $23.81. Val Kennedy, Associate Editor Momenta Pharmaceuticals Inc. Forty...
BioCentury | Jun 21, 2019
Politics, Policy & Law

Fearmongering about China diminishes American life sciences competitiveness

...an investment in the online patient platform PatientsLikeMe and reportedly scuttled a Chinese investment in Momenta Pharmaceuticals Inc....
...see “CFIUS Drawing Line In Sand On Personal Data” and “CFIUS Influence May Have Prompted Momenta’s...
...not necessarily reflect the views of BioCentury. Companies and Institutions Mentioned iCarbonX Inc. (Shenzhen, China) Momenta Pharmaceuticals Inc....
BioCentury | Jun 5, 2019
Finance

Conflicts over scale, response to foreign threats and espionage against NIH research at Senate hearing

...an online platform for patients to share health information, and prevented a Chinese investment in Momenta Pharmaceuticals Inc....
...“CFIUS Drawing Line In Sand On Personal Data, ” and “CFIUS influence May Have Prompted Momenta's...
...in “some nefarious activity.” Companies and Institutions Mentioned Oregon Health & Science University, Portland, Ore. Momenta Pharmaceuticals Inc....
Items per page:
1 - 10 of 401